Search results
Showing 31 to 45 of 66 results for metastatic prostate cancer
Irreversible electroporation for treating prostate cancer (IPG768)
Evidence-based recommendations on irreversible electroporation for treating prostate cancer. This involves using electrical pulses to destroy the cancer cells.
View recommendations for IPG768Show all sections
Awaiting development [GID-TA11557] Expected publication date: TBC
High-intensity focused ultrasound for prostate cancer (IPG118)
Evidence-based recommendations on high-intensity focused ultrasound for treating prostate cancer. This involves inserting a probe through the rectum that gives out a beam of ultrasound to heat and destroy the cancerous prostate tissue.
Awaiting development [GID-TA11558] Expected publication date: TBC
Awaiting development [GID-TA11438] Expected publication date: TBC
Awaiting development [GID-TA11202] Expected publication date: TBC
Awaiting development [GID-TA11114] Expected publication date: TBC
Awaiting development [GID-TA11534] Expected publication date: TBC
Awaiting development [GID-TA11049] Expected publication date: TBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]
In development [GID-TA10904] Expected publication date: TBC
Axumin for functional imaging of prostate cancer recurrence (MIB172)
NICE has developed a medtech innovation briefing (MIB) on Axumin for functional imaging of prostate cancer recurrence .